These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11154897)

  • 1. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
    Reichert JM; Healy EM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
    Jokura Y; Yano K; Yamato M
    J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
    Rawson NS
    Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to watch in 2020.
    Kaplon H; Muralidharan M; Schneider Z; Reichert JM
    MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study.
    Cai Y; Sui L; Wang J; Qian W; Peng Y; Gong L; Wu W; Gao Y
    BMC Med; 2024 Sep; 22(1):421. PubMed ID: 39334246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study.
    Hwang TJ; Sokolov E; Franklin JM; Kesselheim AS
    BMJ; 2016 Jun; 353():i3323. PubMed ID: 27352914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
    da Costa Gonçalves F; Demirci E; Zwiers A
    Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.
    Reichert JM
    Trends Biotechnol; 2000 Sep; 18(9):364-9. PubMed ID: 10942959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.